A six month mitotane course induced sustained correction of hypercortisolism in a young woman with PPNAD and Carney complex

Journal of Endocrinological Investigation

Volumn 28, Issue 3, 2005, Pages 54-60

  Cignarelli, M ^a,c   Picca, G ^a   Campo, M ^a   Margaglione, M ^a   Marino, A ^a   Logoluso, F ^b   Giorgino, F ^b  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^c University of Bari School of Medicine ^*  (Italy)

Author keywords

Adrenocortical cancer; Carney complex; Cushing's syndrome; Mitotane; PPNAD

Indexed keywords

ANGIOPEPTIN; CHOLESTEROL; HYDROCORTISONE; KETOCONAZOLE; MITOTANE; PREDNISONE; THYROXINE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DNA; METALLOTHIONEIN; STEROID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACNE; ADRENAL CORTEX INSUFFICIENCY; ADRENAL INSUFFICIENCY; ADULT; ANAMNESIS; ARTICLE; CARNEY COMPLEX; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCORTISOLISM; LOW DRUG DOSE; MENSTRUATION; SEBORRHEA; SIDE EFFECT; STOMACH DISEASE; ADRENAL CORTEX DISEASE; ADRENAL GLAND; BLOOD; GENETICS; LONG TERM CARE; MULTIPLE ENDOCRINE NEOPLASIA; PATHOLOGY; PIGMENT DISORDER; RADIOGRAPHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNDROME; URINE;

ADRENAL CORTEX DISEASES; ADRENAL GLANDS; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; DNA; FEMALE; HUMANS; HYDROCORTISONE; LONG-TERM CARE; METALLOTHIONEIN; MITOTANE; MULTIPLE ENDOCRINE NEOPLASIA; PIGMENTATION DISORDERS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEROIDS; SYNDROME; TOMOGRAPHY, X-RAY COMPUTED;

EID: 21344432094     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03345530     Document Type: Article

References (26)

1. Benecke R, Keller E, Vetter, de Zeeuw RA. Plasma level monitoring of MT (o,p′-DDD) and its metabolite (o,p′-DDE) during long-term treatment of Cushing's disease with low doses. Eur J Clin Pharmacol 1991, 41: 259-61.
2. Wooten MD, King DK. Adrenal cortical carcinoma: epidemiology and treatment with MT and a review of the literature. Cancer 1993, 72: 3145-55.
3. Bakke JE, Bergman AL, Larsen GL. Metabolism of 2,4′,5- trichlorobiphenyl by the mercapturic acid pathway. Science 1982, 217: 645-7.
4. Jonsson CJ, Rodriguez-Martinez H, Lund BO, Bergman A, Brandt I. Adrenocortical toxicity of 3-methylsulfonyl-DDE in mice. II. Mitochondrial changes following ecologically relevant doses. Fundam Appl Toxicol 1991, 16: 365-74.
5. Jönsson CJ, Lund BO. In vitro bioactivation of the environmental pollutant 3-methylsulphonyl-2,2-bis(4-chlorophenyl)-1,1-dichloroethene in the human adrenal gland. Toxicol Lett 1994, 71: 169-75.
6. Stratakis CA, Carney JA, Lin JP, et al. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. J Clin Invest 1996, 97: 699-05.
7. Stratakis CA, Jenkins RB, Pras E, et al. Cytogenetic and microsatellite alterations in tumors from patients with the syndrome of myxomas, spotted skin pigmentation, and endocrine overactivity (Carney complex). J Clin Endocrinol Metab 1996, 81: 3607-14.
8. Kirschner LS, Carney JA, Pack SD, et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet 2000, 26: 89-92.
9. Raux Demay MC, Netchine I, Stratakis C, Filipe G, Blanchet C, Carney JA. Two cases of Cushing's syndrome related to the Carney complex and controlled by op′DDD. Program of the Pediatric Academic Societies' Annual Meeting, Montreal, 2001, p 1-721 (abstract).
10. Stratakis CA, Sarlis N, Kirschner LS, et al. Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease. Ann Intern Med 1999, 13: 585-91.
11. Baudin E, Pellegriti G, Bonnay M, et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p′DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001, 92: 1385-92.
12. Margaglione M, Di Minno G, Grandone E, et al. Raised plasma fibrinogen concentrations in subjects attending a metabolic ward-relation to family history and vascular risk factors. Thromb Haemost 1995, 73: 579-83.
13. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001, 86: 4041-6.
14. Casey M, Vaughan CJ, He J, et al. CT 2000 Mutations in the protein kinase A R1 regulatory subunit cause familial cardiac myxomas and Carney complex. J Clin Invest 106: 31-8.
15. Vaughan CJ, Veugelers M, Basson CT. Tumors and the heart: molecular genetic advances. Curr Opin Cardiol 2001, 16: 195-00.
16. Basson CT, Aretz HT. A 27-year-old woman with two intracardiac masses and a history of endocrinopathy. N Engl J Med 2002, 346: 1152-8.
17. Sizonenko PC, Doret AM, Riondel AM, Paunier L. Cushing's syndrome due to bilateral adrenal cortical hyperplasia in a 13-year old girl: successful treatment with o,p′-DDD. Helv Paediatr Acta 1974, 29: 195-02.
18. Pichler E. Therapy of a Cushing syndrome caused by hyperplasia of the adrenal cortex in a 7-year old girl with the adrenal cortex blocking agent o,p′-DDD. Helv Paediatr Acta 1966, 21: 447-74.
19. Heilmann P, Wagner P, Nawroth PP, Ziegler R. Therapy of the adrenocortical carcinoma with Lysodren (o,p′-DDD). Therapeutic management by monitoring o,p′-DDD blood levels. Med Klin (Munich) 2001, 96: 371-7.
20. Haak HR, Hermans J, van de Velde CJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994, 69: 947-51.
21. Terzolo M, Pia A, Berruti A, et al. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab 2000, 85: 2234-8.
22. Takamatsu J, Kitazawa A, Nakata K, Furukawa K, Nakai Y. Does mitotane reduce endogenous ACTH secretion? N Engl J Med 1981, 305: 957.
23. Kawai S, Ichikawa Y, Kaburaki J, Yoshida T. 18 years mitotane therapy for intractable Cushing's disease. Lancet 1999, 354: 951.
24. Dickerman Z, Kaufman H, Laron Z. Successful treatment of Cushing's disease with o,p′-DDD followed by pituitary irradiation in a 19-year-old male patient. Isr J Med Sci 1979, 15: 455-9.
25. Sacerdote A, Kukar NM, Bleicher SJ, Herrera A, Jubay F Jr. Mitotane and low thyroxine levels. Ann Intern Med 1981, 94: 141.
26. van Seters AP, Moolenaar AJ. Mitotane increases the blood levels of hormonebinding proteins. Acta Endocrinol (Copenh) 1991, 124: 526-33.